Seattle BioMed initiates malaria vax trial

Seattle Biomedical Research Institute said it has officially started the first human clinical trial of its malaria vaccine candidate. The trial will assess the safety of a genetically engineered version of the malaria parasite. Report

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.